NARRATIVA · INSIGHTS

Agentic AI enterprise solutions for regulatory writing: six gaps to close before you commit

General-purpose AI solutions lack the specific infrastructure needed for regulatory writing in the life sciences sector.

Agentic AI enterprise solutions for regulatory writing: six gaps to close before you commit

General-purpose enterprise AI solutions—such as Anthropic Claude, OpenAI Codex, and Microsoft Copilot—provide powerful foundational capabilities and fast innovation. However, they lack the specific life sciences infrastructure required for regulatory writing. When regulatory teams evaluate whether general enterprise offerings can drive medical writing, six key gaps emerge: GxP compliance and ready-to-use validation packages, complete statement-level traceability and audit trails, strict data protection including zero data retention (ZDR), prebuilt regulatory workflows, seamless deployment fit, and AI sovereignty and model selection. In contrast, purpose-built platforms like Narrativa Navigator integrate third-party large language models (LLMs) within a specialized life sciences orchestration layer engineered for regulatory compliance. This article examines each gap, maps them to the joint EMA/FDA guiding principles, and reviews published evidence on LLM-written trial documents.

Core regulatory expectations for AI in drug development

Regulatory frameworks and standards

Regulatory expectations for artificial intelligence in drug development are framed across several landmark publications. The European Medicines Agency (EMA) Reflection Paper (September 2024) introduced a risk-based framework emphasizing sponsor accountability, while the US Food and Drug Administration (FDA) Non-Binding Draft Guidance (January 2025) outlines non-binding recommendations requiring a defined Context of Use (COU) and credibility evaluations for models shaping regulatory evidence, specifically focusing on evidence-shaping applications rather than routine operational drafting. Industry standards like the ISPE GAMP Guide: AI (July 2025), EU GMP Annex 11, and draft ICH E6(R3) guide GxP validation across the system life cycle. Additionally, the non-binding EMA/FDA Joint Principles (January 2026) established ten high-level guiding principles for global submissions.

Core design principles

Across these frameworks, several core principles dictate how AI systems must be designed. Central to this strategy is a human-centric approach, ensuring qualified experts maintain oversight and accountability. Rather than applying a one-size-fits-all model, agencies favor risk-based validation where technical scrutiny scales directly with the risk of the intended document type—distinguishing operational drafting from tasks that interpret data or shape evidence.

To maintain data integrity, robust governance must ensure end-to-end traceability, complete data lineage, and auditability under regulations like HIPAA and GDPR, while upholding security standards at the model-provider layer. Compliance requires continuous life cycle management—incorporating proactive monitoring, issue tracking, and formal change control to address model updates, drift, and performance over time.

Risk management & evidence

Published peer-reviewed studies evaluated older foundational model architectures. For instance, a study co-authored by Boston Consulting Group (BCG) researchers (Markey et al., 2025) evaluated Retrieval-Augmented Generation (RAG) pipelines on specific clinical trial protocol sections, finding that while LLMs scored high on terminology and relevance, they required structured grounding to maintain factual accuracy and prevent hallucinations. Similarly, Landman et al. (2024) demonstrated that off-the-shelf models struggle with complex table summarization unless guided by tailored domain logic. General-purpose solutions require internal teams to build and maintain complex custom RAG pipelines and table-parsing workflows to mitigate these accuracy risks.

When deploying general-purpose models like Claude, the sponsor must design, document, and validate every pipeline component. A purpose-built platform offers pre-grounded domain infrastructure, but under a risk-based approach, the sponsor ultimately remains accountable for defining the context of use and verifying system outputs.

Where general-purpose models fall short in regulatory writing

To align general enterprise AI capabilities with regulatory expectations, life sciences organizations must evaluate where standard platforms fall short. When examining general-purpose enterprise offerings for medical and regulatory writing, six distinct critical gaps emerge that must be addressed before committing to a deployment.

Gap 1: Compliance, validation, and life cycle control

Regulators expect validation to scale with risk and quality management to cover the whole life of an AI tool. A general-purpose deployment gives you neither ready-made.

  • No validation package to inherit. Your team defines the context of use, assesses model risk along the lines of FDA’s draft credibility framework, validates against 21 CFR Part 11, EU GMP Annex 11, GAMP 5 and the GAMP AI guide, and owns change control. Confirm with Anthropic whether any validation documentation exists for your use.
  • Models change. Models are versioned and retired, and outputs vary from run to run. Requalifying after a model change, and reproducing how a paragraph was generated years later, is hard. This is true of any product built on commercial models, including Navigator. The difference is who runs the change control: with a general-purpose model it is you; with Navigator it is Narrativa, and it is documented for your deployment. GAMP AI treats this as a supplier responsibility, so ask any vendor how they discharge it.
  • Certifications cover the vendor, not your process. Anthropic’s SOC 2 Type II, ISO 27001 and ISO 42001 attest to its own controls. The same is true of Narrativa’s SOC 2 Type II. Your QA team still needs its own risk assessment and SOPs either way.
  • The rules are moving. The EU AI Act entered into force in August 2024, with phased enforcement timelines for high-risk AI obligations through 2026 and beyond. Additionally, the final version of FDA draft guidance and updated EMA roadmaps require ongoing governance reviews.

Navigator provides a life sciences infrastructure layer over third-party models, offering validation support, audit trails, and alignment with 21 CFR Part 11, EU GMP Annex 11, and Annex 22 principles. However, sponsors must verify what documentation is provided versus what validation responsibilities remain with their internal Quality Assurance (QA) team.

Gap 2: Traceability and verification

In regulatory submissions, critical errors include inaccurate references, mistranscribed numbers, and departures from current guidance. For example, Clinical Study Report (CSR) text must remain strictly consistent with backing Tables, Listings, and Figures (TLFs). As evaluated in literature, off-the-shelf LLMs require rigorous grounding and verification workflows to ensure statement-level accuracy and eliminate hallucination risks.

With a general-purpose model, grounding the AI in domain sources, ingesting tabular data in structured formats, linking statements to source records, and tracking verifications require significant internal engineering rather than simple prompt design.

Narrativa Navigator maintains statement-level linking to source records with complete data lineage, audit trails, and integrated human-in-the-loop review workflows. Sponsors should independently evaluate these mechanisms on their own documents, measuring factual accuracy separately from text fluency.

Gap 3: Data protection and zero data retention

For a pharma buyer with a hard ZDR rule, the friction with Claude’s first-party API and apps is concrete and documented by Anthropic itself:

  • The newest models are restricted under ZDR. Anthropic designates certain models as “Covered Models” that require limited retention and review as part of its safety work, so they are not available under ZDR unless Anthropic expressly authorizes it. Check Anthropic’s current Covered Models list and retention period before planning a ZDR deployment, because it changes with each release.
  • ZDR is an agreement, not a setting. It is available to qualified accounts only and is enabled per organization after approval by Anthropic’s sales team. Teams cannot simply switch it on.
  • There are carve-outs. Even under ZDR, Anthropic may retain data where needed to comply with law or combat misuse or harm, and it retains safety-classifier results to enforce its usage policy. These are standard for any processor; the point is that they must be read and accepted, not assumed away.
  • ZDR and HIPAA are separate tracks. Anthropic’s BAA covers its HIPAA-ready services (the API with the HIPAA configuration enabled and HIPAA-ready Enterprise plans) without ZDR, while some paths, such as Claude Code on a Console API key, require ZDR for the BAA to apply. Beta features are generally outside the BAA unless explicitly listed. Which features are covered under which configuration needs checking line by line.
  • ZDR and auditability pull against each other. Anthropic’s Compliance API does not capture Claude Code local-mode sessions where ZDR is in effect, so a full audit trail of AI interactions is something you have to build.
  • Cloud marketplaces change the picture. Claude is also available through AWS Bedrock and Google Vertex AI, where retention, residency and BAA terms are the cloud provider’s rather than Anthropic’s. For many EU sponsors this is the more practical route, and it should be evaluated on its own terms rather than through Anthropic’s first-party policies.

None of this makes Claude unsafe. It makes a blanket, platform-wide ZDR policy hard to guarantee when the most capable models, the audit tooling and the feature set each sit under different rules.

Data retention architecture in Navigator. Navigator distinguishes between two distinct operational layers:

  • Model-provider layer. Prompts and content sent to third-party language models are processed under zero-data-retention agreements with those providers: they are not stored by the provider once the response is returned and are not used for training. Where a provider restricts its newest models under ZDR, those models are not used in ZDR deployments.
  • Platform layer. Documents, drafts, source data, lineage, and audit records persist within the customer’s dedicated tenant under role-based access control to enable authoring, review, and compliance auditing. These records are retained according to the sponsor’s policy and DPA terms, remaining subject to applicable legal hold requirements.

For on-premise and private-cloud deployments, no data leaves your infrastructure and retention follows your own policies.

Gap 4: Purpose-built workflows

Claude is a platform, not a regulatory writing product.

  • No prebuilt regulatory agents. There is no off-the-shelf tooling for regulatory document types. Prompts, templates, skills and connectors are built, maintained and validated by your team.
  • Build versus buy. The flexibility is real, but engineering, validation and upkeep can absorb the savings compared with a vertical platform.

Navigator ships four purpose-built solutions:

  • Medical Authoring Companion: clinical protocols, Statistical Analysis Plans (SAPs), Informed Consent Forms (ICFs), CSRs, Investigator’s Brochures (IBs), Development Safety Update Reports (DSURs), and Periodic Benefit-Risk Evaluation Reports (PBRERs).
  • BioStat Developer: SDTM and ADaM datasets, and TLFs.
  • Narratives Pathway: patient narratives at scale.
  • Redaction Scout: anonymization and redaction.

Gap 5: Deployment and integration

  • Integrations are yours to build. Connecting Claude to a document management or regulatory system such as Veeva Vault is custom work.
  • Residency needs confirming. EU-only data residency for Anthropic’s first-party API and chat interface should be confirmed directly. Bedrock and Vertex AI offer EU regions, with the trade-offs noted above.
  • Personal accounts are a risk. Free, Pro and Max plans fall outside enterprise terms. This applies to standard web applications, but it bites harder when the tool is as accessible as Claude, so writers need SSO, domain capture and clear policy.

Navigator deploys on-cloud natively inside the customer’s own AWS, Azure, or GCP cloud environment (VPC), or on-premise, with REST and GraphQL interfaces and delivery to regulatory systems such as Veeva Vault.

Gap 6: AI sovereignty, model ownership and vendor lock-in

Relying completely on multi-tenant vendor-hosted platform APIs introduces long-term strategic and operational risks regarding data sovereignty, model availability, and price or access lock-in. Organizations dependent on third-party remote cloud services risk operational disruption if service terms change, API access is restricted, or external connections are lost.

  • Third-party platform dependency. Standard cloud hosted models tie critical regulatory operations to continuous external availability and vendor policy updates. If an external provider discontinues a model version or modifies terms, downstream pipelines can break.
  • Full control via private hosting. Hosting open-weight or specialized models locally or within an enterprise’s private cloud infrastructure guarantees complete data sovereignty, eliminates third-party disconnection risks, and ensures uncompromised business continuity.

At a glance: a general-purpose Claude deployment versus Narrativa Navigator

The six gaps outlined above in one view. The right-hand column highlights Narrativa Navigator’s capabilities; please verify as described below.

Issue General-purpose Enterprise AI Deployment (e.g., Claude, OpenAI, Copilot) Narrativa Navigator (Third-Party LLMs + Life Sciences Infrastructure Layer)
AI Sovereignty & Model Ownership Dependent on proprietary third-party hosted APIs; vulnerable to vendor term updates, service disconnections, or model deprecations. Supports private cloud and local hosting of open-weight/specialized models, ensuring complete data sovereignty and uninterrupted business continuity.
Prebuilt Regulatory Workflows None. Prompts, templates, RAG pipelines, and connectors must be built, maintained, and validated internally. Four purpose-built solutions: Medical Authoring Companion, BioStat Developer, Narratives Pathway, and Redaction Scout.
GxP and Validation No pre-packaged validation. You define context of use, assess model credibility, and perform GxP/Part 11 validation. Validation-ready architecture, validation support package, audit trails, and 21 CFR Part 11 alignment.
Model Change Control Managed entirely by the customer team as foundational models update or retire. Managed and documented per deployment by Narrativa within a dedicated governance framework.
Traceability & Verification Requires custom RAG pipelines and table-parsing logic to link statements to source data and prevent hallucinations. Statement-level source grounding, complete data lineage, and an AI quality-review checklist within the workflow.
Audit Trail Standard enterprise logs; gaps exist in local-mode/ZDR sessions requiring custom tracking tools. Complete end-to-end audit trail for user actions, system operations, and content changes maintained in customer tenant.
Zero Data Retention (ZDR) Requires special commercial agreement; newest models restricted; subject to legal and safety retention carve-outs. Guaranteed ZDR at the model-provider layer for all LLMs; document data securely stored and controlled in customer tenant.
Deployment & Residency First-party cloud SaaS or cloud provider instances (AWS Bedrock / GCP Vertex AI). On-cloud deployment inside customer’s AWS, Azure, or GCP VPC, or on-premise.
Integrations Custom development required for life sciences systems like Veeva Vault. Prebuilt REST and GraphQL APIs with native connectors for regulatory platforms (e.g., Veeva Vault).
Security Attestation & Governance Vendor SOC 2 / ISO certifications cover model infrastructure only; governance framework must be built by customer. SOC 2 Type II certified platform, specialized AI Governance Committee, bias evaluation, and alignment with EU AI Act principles.

What to verify before you buy

A published policy is a starting point, not evidence, and that applies to our own pages as much as anyone’s. Whichever platform you evaluate, including ours, ask for these in writing:

  • ZDR terms in the contract and DPA, including the agreements with underlying model providers, which models and features each one covers, and the legal and safety carve-outs.
  • The sub-processor list, with processing locations.
  • The full SOC 2 Type II report under NDA, including scope, observation period and exceptions.
  • The validation package: what is validated by the vendor, what remains yours, and how model changes are controlled and communicated. Ask the vendor to map it to the supplier responsibilities in the GAMP AI guide.
  • 21 CFR Part 11 and Annex 11 coverage, in detail rather than as a label.
  • Where documents, drafts and audit records are stored and for how long, so that ZDR claims and record-keeping obligations are reconciled rather than left in tension.
  • Exit terms and data portability.
  • A pilot on your own documents, scored the way the published studies did: factual accuracy against source tables, provenance of every claim, adherence to current guidance, and lean writing, each rated by your own experts, rather than headline time-savings figures.

In light of the EMA and FDA principles and FDA’s draft credibility framework, add these questions for any AI tool used in regulatory work:

  • Context of use: can the vendor document the defined role and scope of each agent you plan to use, in terms you could reuse in a credibility assessment?
  • Risk-based validation: how does the vendor’s validation support map to the risk of each document type, from a plain-language summary (operational drafting) to a CSR safety section (shaping the evidence)?
  • Life cycle management: how are model changes, drift and issues tracked, communicated and re-evaluated, and how will you be notified?
  • Data governance: can every statement in a draft be traced to a source record, and where is that evidence kept given the vendor’s retention claims?
  • Human interaction: what is measured about reviewer behavior, such as overreliance, rather than only model accuracy? The Pfizer challenge found that where the human sits in the loop changed accuracy more than the prompt did.

About Narrativa

Narrativa Agentic AI solutions unlock a faster, smarter future for life sciences organizations, helping them to efficiently produce complex, high-volume documentation for regulatory and commercialization workflows. By automating content creation, Narrativa delivers greater speed, accuracy, and consistency—while ensuring full compliance in highly regulated environments.

Narrativa Navigator Platform provides secure and specialized Agentic AI-powered automation features. It includes complementary user-friendly tools such as the Medical Authoring Companion for CSR and Protocol generation, BioStat Developer for AI Agents for TLF generation and SDTM and ADaM dataset generation, Narrative Pathway, and Redaction Scout, which operate cohesively to transform clinical data into submission-ready documents for regulatory and commercialization. From database to delivery, pharmaceutical sponsors, biotech firms, and contract research organizations (CROs) rely on Narrativa to streamline workflows, decrease costs, and reduce time-to-market across the clinical lifecycle and, more broadly, throughout their entire businesses.

Explore www.narrativa.com and follow on LinkedIn, Facebook, Instagram, and X.

Need help exploring?

Narrativa SideKick AI Agent can help you discover solutions, success stories & more.

Talk to SideKick AI Agent